期刊文献+

中剂量阿糖胞苷早期强化治疗急性髓系白血病疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨以中剂量阿糖胞苷(ID-Ara-c)为主的早期强化化疗方案对急性髓系白血病(AML)的疗效及其对预后的影响。方法应用标准诱导缓解化疗方案治疗后,早期采用中剂量阿糖胞苷(ID-Ara-c)1.0/m2/12h×6次,配合柔红霉素(DNR)或米托蒽醌(MTZ)早期强化治疗1~2个疗程,后与其他方案交替巩固治疗共6~8个疗程,停药观察疗效。结果16例AML持续完全缓解(CCR)11例(CCR率69%),中位缓解时间15.2个月(5~43个月),复发4例(复发率25%),治疗相关死亡率1例(6%)。结论采用ID-Ara-c为主的早期强化治疗方案提高AML患者的无病生存期,并降低了化疗相关死亡率。
出处 《江西医药》 CAS 2005年第10期636-637,共2页 Jiangxi Medical Journal
  • 相关文献

参考文献3

  • 1Rowe JM,Tellman MS.Intensifying induction therapy in acute myeloid leukemia:has a new standard of cave emerged. Blood, 1997,90:2121.
  • 2Bioshop JF,Matthews JP,Young GA,et al. Arondomized study of highdose cytarabine in induction in acute myeloid leukemia. Blood,1996,87:1710.
  • 3王建祥.急性髓系白血病的化疗[J].白血病.淋巴瘤,2004,13(5):261-265. 被引量:7

共引文献6

同被引文献30

  • 1张志南,沈悌.血液病诊断及疗效标准[M].3版.北京:北京科学出版社,2007:131-134.
  • 2中华医学会儿科学分会血液学组,中华儿科杂志编辑委员会.儿童急性髓细胞白血病诊疗建议[J].中华儿科杂志,2006,44(1):877-878.
  • 3Avramis VI, Biener R, Krailo M,et al. Biochemical pharmacology ofhigh dose 1 -beta -D -arabinofuranosylcytosine in childhood acuteleukemia[J]. Cancer Res, 1987,47(12):6786-6792.
  • 4PlunkettW, Liliemark J0,Estey E,et al. Saturation of ara-CTP ac-cumulation during high -dose ara-C therapy : pharmacologic ratio-nale for intermediate -dose ara-C [J]. Semin Oncol,1987,14(6):159-166.
  • 5ClarkeML,Mackey JR,Baldwin SA,et al. The role of membranetransporters in cellular resistance to anticancer nucleoside drugs[J].Cancer Treat Res,2002,112: 27-47.
  • 6MyersSN,Goyal RK’Roy JD,et al. Functional single nucleotidepolymorphism haplotypes in the human equilibrative nucleosidetransportei{J]. Pharmacogenetics and Genomics,2006,16(5) : 315-20.
  • 7GusellaM ,Pasini F, Bolzonella C ,et al. Equilibrative nucleosidetransporter 1 genotype, cytidine deaminase activity and age predictgemcitabine plasma clearance in patients with solid tumours[J]. BrJ Clin Pharmacol,2011,71 ⑶-.437-44.
  • 8PodgorskaM,Kocbuch K,Pawelczyk T. Recent advances in studieson biochemical and structural p roperties of equilibrative and con-centrative nucleoside transporters [J]. Acta B iochim Pol,2005,52(4): 749-758.
  • 9GalmariniCM, Thomas X, Calvo F,et al. In vivo mechanisms ofresistance to cytarabine in acute myeloid leukaemia [J]. Br JHaematol,2002,117(4) : 860亨868.
  • 10TakagakiK, Katsuma S, Kaminishi Y,et al. Gene -expression pro-filing reveals down -regulation of equilibrative nucleoside trans-porter 1(ENT1) in Ara-C-resistant CCRF-CEM-derived cells[J]. JBiochem, 2004,136(5) :733-40.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部